Raymond Dwek sold $1.1M of UTHR
director at UNITED THERAPEUTICS Corp. 4,000 shares at an average of $284.55, traded Apr 7, 2025, filed Apr 8, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.1M at market
- +20Share of holdings soldSold 70% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +10.1%, 3m +5.3%, 6m +63.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001562180-25-003069, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Apr 7, 2025 | MOption exercise Common Stock10b5-1 | +4,000 | $175.43 | $702k | 5,750 | Apr 8, 2025 |
| Apr 7, 2025 | SOpen-market sale Common Stock10b5-1 | -4,000 | $284.55 | $1.1M | 1,750 | Apr 8, 2025 |
| Apr 7, 2025 | MOption exercise Stock Optionderivative10b5-1 | -4,000 | $0.00 | $0 | 6,000 | Apr 8, 2025 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| Pro nowfree Oct 20, 2026 | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| Pro nowfree Oct 20, 2026 | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| Pro nowfree Oct 16, 2026 | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| Pro nowfree Oct 15, 2026 | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.